Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/80831
DC FieldValueLanguage
dc.contributor.authorMolassiotis, Aen_US
dc.contributor.authorCheng, HLen_US
dc.contributor.authorLeung, KTen_US
dc.contributor.authorLi, YCen_US
dc.contributor.authorWong, KHen_US
dc.contributor.authorAu, JSKen_US
dc.contributor.authorSundar, Ren_US
dc.contributor.authorChan, Aen_US
dc.contributor.authorNg, TRDen_US
dc.contributor.authorSuen, LKPen_US
dc.contributor.authorChan, CWen_US
dc.contributor.authorYorke, Jen_US
dc.contributor.authorLopez, Ven_US
dc.date.accessioned2019-06-12T08:16:55Z-
dc.date.available2019-06-12T08:16:55Z-
dc.date.issued2019-
dc.identifier.citationBrain and behavior, May 2019, e01312, p.1-10, https://doi.org/10.1002/brb3.1312en_US
dc.identifier.urihttp://hdl.handle.net/10397/80831-
dc.description.abstractBackground: Chemotherapy‐induced peripheral neuropathy (CIPN) is a significant and difficult to manage side effect of neurotoxic chemotherapies. Several risk factors for CIPN have been identified to date, but inconsistencies and methodological limitations exist in past research. Also, a limited number of potential risk factors has been investigated in the past.en_US
dc.description.abstractAim: The objective of this study was to assess the relative contribution of a wider range of risk factors in the development of CIPN.en_US
dc.description.abstractMethods: This analysis used the 6‐month data after starting chemotherapy from a larger prospective observational study on CIPN risk, prevalence, and quality of life. Patients were assessed at recruitment for possible CIPN risk factors, including prior history of neuropathies, current/past infectious diseases; neurotoxic medication history; personal and treatment characteristics; smoking history, alcohol use, and vegetable/fruit intake. Neuropathy was assessed at 6‐months after starting chemotherapy with the neuropathy (motor/sensory) items of the NCI‐CTCAE scale and the WHO criterion for neuropathy. Data on symptom burden were also collected.en_US
dc.description.abstractResults: Data were available from 255 patients from three cancer centers in Hong Kong, Singapore, and UK. The use of different scales did not always identify the same predictor variables. Key risk factors in multivariate regression models included older age (highest OR = 1.08, p < 0.01 with the WHO scale), chemotherapy (platinum‐based chemotherapy had OR = 0.20–0.27 in developing CIPN compared to taxane‐based chemotherapy), history of neuropathy (for motor CIPN only, OR = 8.36, p < 0.01), symptom burden (OR = 1.06, p < 0.05), number of chemotherapy cycles received (OR = 1.19–1.24, p < 0.01), and alcohol intake (OR = 0.32, p < 0.05). In univariate analysis, the use of statins was implicated with CIPN (p = 0.03–0.04 with different assessments) and diabetes showed a trend (p = 0.09) in the development of CIPN.en_US
dc.description.abstractConclusion: This study confirmed the CIPN risk related to certain variables and identified new ones. This knowledge can assist with treatment decisions and patient education.en_US
dc.description.sponsorshipSchool of Nursingen_US
dc.language.isoenen_US
dc.publisherJohn Wiley & Sonsen_US
dc.relation.ispartofBrain and behavioren_US
dc.rightsThis is an open access article under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.en_US
dc.rights© 2019 The Authors. Brain and Behavior published by Wiley Periodicals, Inc.en_US
dc.rightsThe following publication Molassiotis, A., Cheng, H. L. , Leung, K. T. , Li, Y. C. , Wong, K. H. , Au, J. S. K., ... & Lopez, V.(2019). Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy. Brain and behavior, 1-10 is available at https://dx.doi.org/10.1002/brb3.1312en_US
dc.subjectCanceren_US
dc.subjectChemotherapy‐induced peripheral neuropathyen_US
dc.subjectPlatinum chemotherapyen_US
dc.subjectRisk factorsen_US
dc.subjectTaxanesen_US
dc.titleRisk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapyen_US
dc.typeJournal/Magazine Articleen_US
dc.identifier.spage1en_US
dc.identifier.epage10en_US
dc.identifier.doi10.1002/brb3.1312en_US
dc.identifier.ros2018000075-
dc.identifier.eissn2162-3279en_US
dc.description.validate201906 bcrcen_US
dc.description.oapublished_finalen_US
Appears in Collections:Journal/Magazine Article
Files in This Item:
File Description SizeFormat 
Molassiotis_Risk_Chemotherapy‐induced_Neuropathy.pdf452.41 kBAdobe PDFView/Open
Access
View full-text via PolyU eLinks SFX Query
Show simple item record
PIRA download icon_1.1View/Download Contents

Page view(s)

60
Citations as of Jul 16, 2019

Download(s)

12
Citations as of Jul 16, 2019

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.